vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and COHEN & STEERS, INC. (CNS). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($284.0M vs $143.8M, roughly 2.0× COHEN & STEERS, INC.). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 24.3%, a 72.1% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs 2.9%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 8.3%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Cohen & Steers is an American investment management company. It focuses on investments in real estate securities via real estate investment trusts (REIT) and alternative income via preferred securities.
ACAD vs CNS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $143.8M |
| Net Profit | $273.6M | $34.9M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | 28.0% |
| Net Margin | 96.3% | 24.3% |
| Revenue YoY | 9.4% | 2.9% |
| Net Profit YoY | 90.3% | -23.9% |
| EPS (diluted) | $1.61 | $0.67 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $284.0M | $143.8M | ||
| Q3 25 | $278.6M | $141.7M | ||
| Q2 25 | $264.6M | $136.1M | ||
| Q1 25 | $244.3M | $134.5M | ||
| Q4 24 | $259.6M | $139.8M | ||
| Q3 24 | $250.4M | $133.2M | ||
| Q2 24 | $242.0M | $121.7M | ||
| Q1 24 | $205.8M | $122.7M |
| Q4 25 | $273.6M | $34.9M | ||
| Q3 25 | $71.8M | $41.7M | ||
| Q2 25 | $26.7M | $36.8M | ||
| Q1 25 | $19.0M | $39.8M | ||
| Q4 24 | $143.7M | $45.8M | ||
| Q3 24 | $32.8M | $39.7M | ||
| Q2 24 | $33.4M | $31.8M | ||
| Q1 24 | $16.6M | $34.0M |
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — | ||
| Q1 24 | 88.8% | — |
| Q4 25 | 6.1% | 28.0% | ||
| Q3 25 | 12.8% | 34.5% | ||
| Q2 25 | 12.2% | 31.8% | ||
| Q1 25 | 7.9% | 33.6% | ||
| Q4 24 | 59.1% | 35.3% | ||
| Q3 24 | 12.6% | 33.7% | ||
| Q2 24 | 12.6% | 31.5% | ||
| Q1 24 | 7.4% | 32.8% |
| Q4 25 | 96.3% | 24.3% | ||
| Q3 25 | 25.8% | 29.4% | ||
| Q2 25 | 10.1% | 27.1% | ||
| Q1 25 | 7.8% | 29.6% | ||
| Q4 24 | 55.4% | 32.8% | ||
| Q3 24 | 13.1% | 29.8% | ||
| Q2 24 | 13.8% | 26.1% | ||
| Q1 24 | 8.0% | 27.7% |
| Q4 25 | $1.61 | $0.67 | ||
| Q3 25 | $0.42 | $0.81 | ||
| Q2 25 | $0.16 | $0.72 | ||
| Q1 25 | $0.11 | $0.77 | ||
| Q4 24 | $0.86 | $0.89 | ||
| Q3 24 | $0.20 | $0.77 | ||
| Q2 24 | $0.20 | $0.63 | ||
| Q1 24 | $0.10 | $0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $145.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $562.0M |
| Total Assets | $1.6B | $876.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $177.7M | $145.5M | ||
| Q3 25 | $258.0M | $98.1M | ||
| Q2 25 | $253.6M | $95.4M | ||
| Q1 25 | $217.7M | $65.2M | ||
| Q4 24 | $319.6M | $183.0M | ||
| Q3 24 | $155.1M | $106.5M | ||
| Q2 24 | $177.1M | $122.0M | ||
| Q1 24 | $204.7M | $99.5M |
| Q4 25 | $1.2B | $562.0M | ||
| Q3 25 | $917.3M | $550.3M | ||
| Q2 25 | $822.4M | $528.5M | ||
| Q1 25 | $765.2M | $507.7M | ||
| Q4 24 | $732.8M | $511.7M | ||
| Q3 24 | $577.2M | $491.0M | ||
| Q2 24 | $516.7M | $463.2M | ||
| Q1 24 | $464.0M | $378.9M |
| Q4 25 | $1.6B | $876.7M | ||
| Q3 25 | $1.3B | $801.6M | ||
| Q2 25 | $1.2B | $751.0M | ||
| Q1 25 | $1.1B | $834.9M | ||
| Q4 24 | $1.2B | $812.4M | ||
| Q3 24 | $976.9M | $727.8M | ||
| Q2 24 | $914.1M | $784.1M | ||
| Q1 24 | $855.1M | $680.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $-120.4M |
| Free Cash FlowOCF − Capex | — | $-126.4M |
| FCF MarginFCF / Revenue | — | -87.9% |
| Capex IntensityCapex / Revenue | — | 4.2% |
| Cash ConversionOCF / Net Profit | -0.18× | -3.45× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-253.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-48.7M | $-120.4M | ||
| Q3 25 | $74.3M | $55.1M | ||
| Q2 25 | $64.0M | $-67.6M | ||
| Q1 25 | $20.3M | $-108.9M | ||
| Q4 24 | $40.4M | $96.7M | ||
| Q3 24 | $63.2M | $25.6M | ||
| Q2 24 | $25.0M | $31.4M | ||
| Q1 24 | $29.1M | $4.9M |
| Q4 25 | — | $-126.4M | ||
| Q3 25 | $73.9M | $52.6M | ||
| Q2 25 | — | $-69.8M | ||
| Q1 25 | — | $-110.0M | ||
| Q4 24 | — | $85.0M | ||
| Q3 24 | $63.2M | $24.2M | ||
| Q2 24 | — | $27.1M | ||
| Q1 24 | — | $537.0K |
| Q4 25 | — | -87.9% | ||
| Q3 25 | 26.5% | 37.1% | ||
| Q2 25 | — | -51.3% | ||
| Q1 25 | — | -81.8% | ||
| Q4 24 | — | 60.8% | ||
| Q3 24 | 25.2% | 18.2% | ||
| Q2 24 | — | 22.3% | ||
| Q1 24 | — | 0.4% |
| Q4 25 | — | 4.2% | ||
| Q3 25 | 0.1% | 1.8% | ||
| Q2 25 | — | 1.6% | ||
| Q1 25 | — | 0.8% | ||
| Q4 24 | — | 8.3% | ||
| Q3 24 | 0.0% | 1.1% | ||
| Q2 24 | — | 3.5% | ||
| Q1 24 | — | 3.5% |
| Q4 25 | -0.18× | -3.45× | ||
| Q3 25 | 1.03× | 1.32× | ||
| Q2 25 | 2.40× | -1.84× | ||
| Q1 25 | 1.07× | -2.74× | ||
| Q4 24 | 0.28× | 2.11× | ||
| Q3 24 | 1.93× | 0.65× | ||
| Q2 24 | 0.75× | 0.99× | ||
| Q1 24 | 1.76× | 0.14× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
CNS
Segment breakdown not available.
